In our cohort, MYD88 was the most frequently mutated in CD5+ non-DE DLBCL, consistent with the previous results that MYD88 mutation is supposed to be a genetic feature of CD5+ DLBCL (28, 29). Here, CD5 is linked to diffuse large B-cell lymphoma.